ARM 2020 report: $19.9B invested in industry


As per the latest report from the Alliance for Regenerative Medicine (ARM), sector financing reached $19.9B in 2020, doubling from the previous year. It is likely 2021 will be a record year for the number of regulatory decisions on new regenerative medicine products.

Full report available here.

Highlights from ARM’s annual report and full-year 2020 data include:

– There were 1,085 developers of cell, gene, and tissue-based therapies active worldwide at the end of 2020, an increase of about 100 developers from the previous year
– There were 1,220 clinical trials ongoing at the end of 2020: 383 in Phase 1, 685 in Phase 2, and 152 in Phase 3
– 14 regenerative medicine companies went public in 2020, compared to 6 in 2018 and 12 in 2018
– Publicly traded regenerative medicine companies saw a roughly 44% increase in performance in 2020, easily outpacing the 23% rise in the NASDAQ Biotech Index
– Gene therapy financing was up 73% in 2020 from the previous year, while cell therapy financing was up 160%

About the Alliance for Regenerative Medicine

The Alliance for Regenerative Medicine (ARM) is the leading international advocacy organisation dedicated to realizing the promise of advanced therapy medicinal products (ATMPs). ARM promotes legislative, regulatory and reimbursement initiatives in Europe and internationally to advance this innovative and transformative sector, which includes cell therapies, gene therapies and tissue-based therapies. Early products to market have demonstrated profound, durable and potentially curative benefits that are already helping thousands of patients worldwide, many of whom have no other viable treatment options. Hundreds of additional product candidates contribute to a robust pipeline of potentially life-changing ATMPs. In its 11-year history, ARM has become the global voice of the sector, representing the interests of 380+ members worldwide and 85+ members across 15 European countries, including small and large companies, academic research institutions, major medical centres and patient groups. To learn more about ARM or to become a member, visit